During a live event, Yelena Y. Janjigian, MD, moderated a discussion on how to use PD-L1 CPS status when considering ...

James Essell, MD, Sarah Cannon Research Institute at OHC, the US Oncology Network, discusses the benefits of a remote ...

Remote therapeutic monitoring significantly lowers infection-related hospitalizations in hematological cancer patients, ...

The LimiTEC trial explored teclistamab discontinuation in multiple myeloma, showing comparable outcomes to continuous therapy with a median PFS of 19.9 months. Fixed-duration therapy may reduce ...

A 6-month complete response predicts improved long-term survival in high-risk large B-cell lymphoma patients treated with axicabtagene ciloleucel. Results presented at the 2025 ASH Annual Meeting & ...

XmAb819 demonstrated a manageable safety profile with primarily grade 1 or 2 cytokine release syndrome and no neurotoxicity in ccRCC patients. The trial involved 69 patients, with a 25% objective ...

Patients who have metastatic chromophobe renal cell carcinoma (ChrRCC) that harbors sarcomatoid features (SF) benefited from immunotherapy (IO)-containing regimens vs patients wit ...

James Essell, MD, is a medical oncologist at Sarah Cannon Research Institute at OHC, the US Oncology Network. Remote therapeutic monitoring significantly lowers infection-related hospitalizations in ...

Axatilimab showed a consistent safety profile in cGVHD patients, with no new safety signals and a decrease in TEAEs over time. The AGAVE-201 trial led to FDA approval of axatilimab at 0.3 mg/kg every ...

Zanubrutinib and venetoclax combination shows an 87% 36-month PFS rate in CLL/SLL patients, regardless of del (17p)/TP53 or IGHV status. The SEQUOIA trial demonstrates durable minimal residual disease ...

Nearly one-third of families face catastrophic financial toxicity during pediatric ALL treatment, with significant household material hardship and income loss. Factors increasing HMH risk include ...

New trials reveal INCA033989 shows promise for treating CALR exon 9-mutated myelofibrosis, demonstrating efficacy and tolerability in patients.